Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.07.
Forward PE Ratio (17.07) = Close Price ($92.39) / Consensus Forward EPS ($5.52)
FORWARD PE RATIO
17.07
SECTOR MEDIAN · HEALTHCARE
20.12
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-15.14%
vs the sector median at left
Medtronic plc
Market Cap
$118.26B
Forward PE Ratio
17.07
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Medtronic plc (MDT) | $118.26B | 17.07 |
| CVS Health Corp. (CVS)vs › | $122.58B | 12.09 |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.70B | 33.96 |
| Stryker Corporation (SYK)vs › | $105.97B | 20.18 |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 9.64 |
| McKesson Corporation (MCK)vs › | $104.10B | 23.28 |
| Sanofi (SNY)vs › | $103.62B | N/A |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 29.13 |
| GSK plc (GSK)vs › | $97.25B | 13.93 |
| Danaher Corporation (DHR)vs › | $144.25B | 24.42 |
Trailing P/E
23.2
reported TTM EPS
Forward P/E
17.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $5.52 implies +36.0% EPS growth vs the reported trailing $4.06.
At today's $92.39 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-04-24 | $5.97 | $5.89 – $6.01 | 15 | 15.5x |
| 2028-04-24 | $6.40 | $6.22 – $6.60 | 16 | 14.4x |
| 2029-04-24 | $6.93 | $6.07 – $7.40 | 6 | 13.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
